Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Molecular architecture of the Jumonji C family histone demethylase KDM5B.

Dorosz J, Kristensen LH, Aduri NG, Mirza O, Lousen R, Bucciarelli S, Mehta V, Sellés-Baiget S, Solbak SMØ, Bach A, Mesa P, Hernandez PA, Montoya G, Nguyen TTTN, Rand KD, Boesen T, Gajhede M.

Sci Rep. 2019 Mar 11;9(1):4019. doi: 10.1038/s41598-019-40573-y.

2.

Microfluidics-based self-assembly of peptide-loaded microgels: Effect of three dimensional (3D) printed micromixer design.

Borro BC, Bohr A, Bucciarelli S, Boetker JP, Foged C, Rantanen J, Malmsten M.

J Colloid Interface Sci. 2019 Mar 7;538:559-568. doi: 10.1016/j.jcis.2018.12.010. Epub 2018 Dec 4.

PMID:
30551068
3.

Size-exclusion chromatography small-angle X-ray scattering of water soluble proteins on a laboratory instrument.

Bucciarelli S, Midtgaard SR, Nors Pedersen M, Skou S, Arleth L, Vestergaard B.

J Appl Crystallogr. 2018 Nov 9;51(Pt 6):1623-1632. doi: 10.1107/S1600576718014462. eCollection 2018 Dec 1.

4.

Effects of oxidation on the physicochemical properties of polyunsaturated lipid membranes.

Parra-Ortiz E, Browning KL, Damgaard LSE, Nordström R, Micciulla S, Bucciarelli S, Malmsten M.

J Colloid Interface Sci. 2019 Mar 7;538:404-419. doi: 10.1016/j.jcis.2018.12.007. Epub 2018 Dec 3.

PMID:
30530078
5.

Dramatic influence of patchy attractions on short-time protein diffusion under crowded conditions.

Bucciarelli S, Myung JS, Farago B, Das S, Vliegenthart GA, Holderer O, Winkler RG, Schurtenberger P, Gompper G, Stradner A.

Sci Adv. 2016 Dec 7;2(12):e1601432. eCollection 2016 Dec.

6.

Extended Law of Corresponding States Applied to Solvent Isotope Effect on a Globular Protein.

Bucciarelli S, Mahmoudi N, Casal-Dujat L, Jéhannin M, Jud C, Stradner A.

J Phys Chem Lett. 2016 May 5;7(9):1610-5. doi: 10.1021/acs.jpclett.6b00593. Epub 2016 Apr 18.

7.

HMGB1 binds to the rs7903146 locus in TCF7L2 in human pancreatic islets.

Zhou Y, Oskolkov N, Shcherbina L, Ratti J, Kock KH, Su J, Martin B, Oskolkova MZ, Göransson O, Bacon J, Li W, Bucciarelli S, Cilio C, Brazma A, Thatcher B, Rung J, Wierup N, Renström E, Groop L, Hansson O.

Mol Cell Endocrinol. 2016 Jul 15;430:138-45. doi: 10.1016/j.mce.2016.01.027. Epub 2016 Feb 1.

PMID:
26845344
8.

Unusual dynamics of concentration fluctuations in solutions of weakly attractive globular proteins.

Bucciarelli S, Casal-Dujat L, De Michele C, Sciortino F, Dhont J, Bergenholtz J, Farago B, Schurtenberger P, Stradner A.

J Phys Chem Lett. 2015 Nov 19;6(22):4470-4. doi: 10.1021/acs.jpclett.5b02092. Epub 2015 Oct 29.

9.

Hard sphere-like glass transition in eye lens α-crystallin solutions.

Foffi G, Savin G, Bucciarelli S, Dorsaz N, Thurston GM, Stradner A, Schurtenberger P.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16748-53. doi: 10.1073/pnas.1406990111. Epub 2014 Nov 10.

10.

Cluster-driven dynamical arrest in concentrated lysozyme solutions.

Cardinaux F, Zaccarelli E, Stradner A, Bucciarelli S, Farago B, Egelhaaf SU, Sciortino F, Schurtenberger P.

J Phys Chem B. 2011 Jun 9;115(22):7227-37. doi: 10.1021/jp112180p. Epub 2011 Apr 29.

PMID:
21528887
11.

The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome.

Bucciarelli S, Espinosa G, Cervera R.

Lupus. 2009 Sep;18(10):905-12. doi: 10.1177/0961203309106833.

PMID:
19671791
12.

Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".

Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G, Shoenfeld Y, Ingelmo M, Espinos G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum On Antiphospholipid Antibodies).

J Autoimmun. 2009 May-Jun;32(3-4):240-5. doi: 10.1016/j.jaut.2009.02.008. Epub 2009 Mar 26.

PMID:
19324520
13.

Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse.

Bucciarelli S, Erkan D, Espinosa G, Cervera R.

Clin Rev Allergy Immunol. 2009 Jun;36(2-3):80-4. doi: 10.1007/s12016-008-8107-9. Review.

PMID:
19051065
14.

Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.

Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, Zeher MM, Tincani A, Kontopoulou-Griva I, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernández-Nebro A, Piette JC, Espinosa G, Bucciarelli S, Pisoni CN, Bertolaccini ML, Boffa MC, Hughes GR; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies).

Ann Rheum Dis. 2009 Sep;68(9):1428-32. doi: 10.1136/ard.2008.093179. Epub 2008 Sep 18.

PMID:
18801761
15.

Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors.

Espinosa G, Bucciarelli S, Asherson RA, Cervera R.

Semin Thromb Hemost. 2008 Apr;34(3):290-4. doi: 10.1055/s-0028-1082274. Review.

PMID:
18720310
16.

Executive functions: performance-based measures and the behavior rating inventory of executive function (BRIEF) in adolescents with attention deficit/hyperactivity disorder (ADHD).

Toplak ME, Bucciarelli SM, Jain U, Tannock R.

Child Neuropsychol. 2009 Jan;15(1):53-72. doi: 10.1080/09297040802070929.

PMID:
18608232
17.

[Membrane platelet fatty acids: biochemical characterisation of the ischemic cardiovascular disease, characteristics of the paediatric age, through an artificial neural network interpretation].

Cocchi M, Tonello L, Cappello G, Tarozzi G, Nabacino L, Pastorini E, Bucciarelli S, Solazzo L, De Luca M, Visci G, Caramia G.

Pediatr Med Chir. 2008 Jan-Feb;30(1):25-30. Review. Italian.

PMID:
18491675
18.

Amputation of digits or limbs in patients with antiphospholipid syndrome.

Asherson RA, Cervera R, Klumb E, Stojanovic L, Sarzi-Puttini P, Yinh J, Bucciarelli S, Espinosa G, Levy R, Shoenfeld Y.

Semin Arthritis Rheum. 2008 Oct;38(2):124-31. doi: 10.1016/j.semarthrit.2007.10.013. Epub 2008 Feb 21.

PMID:
18206213
19.

Relapsing catastrophic antiphospholipid syndrome: report of three cases.

Asherson RA, Espinosa G, Menahem S, Yinh J, Bucciarelli S, Bosch X, Cervera R.

Semin Arthritis Rheum. 2008 Jun;37(6):366-72. Epub 2007 Oct 30.

PMID:
17977582
20.

Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"--a tribute to the late Josep Font.

Cervera R, Bucciarelli S, Espinosa G, Gómez-Puerta JA, Ramos-Casals M, Shoenfeld Y, Piette JC, Asherson RA.

Ann N Y Acad Sci. 2007 Jun;1108:448-56. Review.

PMID:
17894009
21.

Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients.

García-Carrasco M, Galarza C, Gómez-Ponce M, Cervera R, Rojas-Rodríguez J, Espinosa G, Bucciarelli S, Gómez-Puerta JA, Bové A, Escárcega RO, Font J.

Lupus. 2007;16(5):366-73.

PMID:
17576741
22.

The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome.

Miesbach W, Asherson RA, Cervera R, Shoenfeld Y, Puerta JG, Espinosa G, Bucciarelli S; Members of the CAPS Registry Group.

Clin Rheumatol. 2007 Dec;26(12):2109-2114. doi: 10.1007/s10067-007-0634-x. Epub 2007 May 24.

PMID:
17522949
23.

The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus.

Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R; Catastrophic Antiphospholipid Syndrome Project Group.

J Rheumatol. 2007 Feb;34(2):346-52.

PMID:
17304658
24.

Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases.

Gómez-Puerta JA, Cervera R, Espinosa G, Asherson RA, García-Carrasco M, da Costa IP, Andrade DC, Borba EF, Makatsaria A, Bucciarelli S, Ramos-Casals M, Font J.

Ann Rheum Dis. 2007 Jun;66(6):740-6. Epub 2007 Jan 12. Review.

25.

Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS.

Cervera R, Espinosa G, Cordero A, Oltra MR, Unzurrunzaga A, Rossiñol T, Plaza J, Bucciarelli S, Ramos-Casals M, Ingelmo M, Asherson RA, Font J; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group.

Semin Arthritis Rheum. 2007 Apr;36(5):287-96. Epub 2007 Jan 3. Review.

PMID:
17207521
26.

The catastrophic antiphospholipid (Asherson's) syndrome and malignancies.

Miesbach W, Asherson RA, Cervera R, Shoenfeld Y, Gomez Puerta J, Bucciarelli S, Espinoza G, Font J; Members of CAPS Registry Group.

Autoimmun Rev. 2006 Dec;6(2):94-7. Epub 2006 Jul 21. Review.

PMID:
17138251
27.

Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome.

Gómez-Puerta JA, Cervera R, Espinosa G, Bucciarelli S, Font J.

Autoimmun Rev. 2006 Dec;6(2):85-8. Epub 2006 Jul 20. Review.

PMID:
17138249
28.

Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry.

Cervera R, Espinosa G, Bucciarelli S, Gómez-Puerta JA, Font J.

Autoimmun Rev. 2006 Dec;6(2):81-4. Epub 2006 Jul 21. Review.

PMID:
17138248
29.

Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors.

Bucciarelli S, Cervera R, Espinosa G, Gómez-Puerta JA, Ramos-Casals M, Font J.

Autoimmun Rev. 2006 Dec;6(2):72-5. Epub 2006 Jul 21. Review.

PMID:
17138246
30.

Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome.

Espinosa G, Bucciarelli S, Cervera R, Gómez-Puerta JA, Font J.

Autoimmun Rev. 2006 Dec;6(2):68-71. Epub 2006 Jul 18. Review.

PMID:
17138245
31.

Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients.

Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, Font J, Asherson RA; European Forum on Antiphospholipid Antibodies.

Arthritis Rheum. 2006 Aug;54(8):2568-76.

32.

Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients.

Gómez-Puerta JA, Cervera R, Espinosa G, Aguiló S, Bucciarelli S, Ramos-Casals M, Ingelmo M, Asherson RA, Font J.

Semin Arthritis Rheum. 2006 Apr;35(5):322-32. Review.

PMID:
16616155
33.

The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients.

Bucciarelli S, Espinosa G, Asherson RA, Cervera R, Claver G, Gómez-Puerta JA, Ramos-Casals M, Ingelmo M; Catastrophic Antiphospholipid Syndrome Registry Project Group.

Ann Rheum Dis. 2006 Jan;65(1):81-6. Epub 2005 May 26.

34.

Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients.

Asherson RA, Espinosa G, Cervera R, Gómez-Puerta JA, Musuruana J, Bucciarelli S, Ramos-Casals M, Martínez-González AL, Ingelmo M, Reverter JC, Font J, Triplett DA.

Ann Rheum Dis. 2005 Jun;64(6):943-6.

35.

Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome.

Cervera R, Font J, Gómez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, Ramos-Casals M, Ingelmo M, Piette JC, Shoenfeld Y, Asherson RA; Catastrophic Antiphospholipid Syndrome Registry Project Group.

Ann Rheum Dis. 2005 Aug;64(8):1205-9. Epub 2005 Feb 11.

36.

Susac's syndrome or catastrophic antiphospholipid syndrome?

Bucciarelli S, Cervera R, Martínez M, Latorre X, Font J.

Lupus. 2004;13(8):607-8.

PMID:
15462492
37.

Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients.

Gómez-Puerta JA, Cervera R, Calvo LM, Gómez-Ansón B, Espinosa G, Claver G, Bucciarelli S, Bové A, Ramos-Casals M, Ingelmo M, Font J.

Rheumatology (Oxford). 2005 Jan;44(1):95-9. Epub 2004 Sep 14. Review.

PMID:
15367749
38.

Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies.

Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, de la Red G, Gil V, Ingelmo M, Font J, Asherson RA.

Ann Rheum Dis. 2004 Jun;63(6):730-6. Review.

39.

Pathophysiological features of hypertension in CAPD: hemodynamic pattern evaluated by impedance cardiography.

Di Paolo B, Santoferrara A, Del Rosso G, Di Liberato L, Amoroso L, Fiederling B, Bucciarelli S, Paolantonio L, Albertazzi A.

Contrib Nephrol. 1994;106:186-9. No abstract available.

PMID:
8174369
40.

Effects of subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.

Di Paolo B, Marini A, Fiederling B, Di Liberato L, Santarelli P, Bucciarelli S, Stuard S, Paolantonio L, Albertazzi A.

Perit Dial Int. 1993;13 Suppl 2:S538-40.

PMID:
8399659
41.

Incidence and pathophysiology of hypertension in continuous ambulatory peritoneal dialysis.

Di Paolo B, Di Liberato L, Fiederling B, Stuard S, Marini A, Bucciarelli S, Santoferrara A, Santarelli P, Albertazzi A.

Perit Dial Int. 1993;13 Suppl 2:S396-8. No abstract available.

PMID:
8399621
42.

Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment.

Di Paolo B, Di Liberato L, Fiederling B, Catucci G, Bucciarelli S, Paolantonio L, Albertazzi A.

ASAIO J. 1992 Jul-Sep;38(3):M477-80.

PMID:
1457906

Supplemental Content

Loading ...
Support Center